knowledge -WSS

knowledge

author：focus 2025-10-02 21:07:23 - browse：2727

Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Ebola public health emergency is over, WHO declares

WSS

Norman Reedus' Daryl Dixon

KalVista pill reduced swelling 'attacks' caused by genetic disease

The dental labor crisis is a moment of opportunity

Senators start work on Medicare physician payment reform

The Readout: Gilead, Bernie Sanders, and other pharma news

How digital tools helped lower hypertension in marginalized patients

knowledge

knowledge

focus

Apple is now the first public company to be valued at $3 trillion

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

BioMarin wins approval for gene therapy to treat hemophilia A

DOJ, FTC to increase scrutiny of all types of health care mergers

Peter Hotez and the public health issue of online harassment

Key House Republican on health care plans exit from Congress

In Memoriam: Notable people who died in 2023

Medical experts are missing from AI regulatory conversations

Supreme Court strikes down use of affirmative action

The kidney, in all its complexity, is captured in a new atlas

focus

Biden report: The neurospychology of memory and aging

Man who had jail sentence commuted by Trump arrested again

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

Medicare Advantage proposed rates disappoint insurers

KalVista pill reduced swelling 'attacks' caused by genetic disease

Man who had jail sentence commuted by Trump arrested again

entertainment

focus

hotspot

leisure time